Inhibition of the degeneration expansion by anti‐HMGB1 antibody and suppression of necrosis by AAV‐YAP both have therapeutic effects, and they are complementary and synergic as therapeutics targeting sequential phases in the ultra‐early phase pathology of AD (Fig. 3). The gene discussed is HMGB1; the disease is Alzheimer disease.